The data presented here demonstrate that a large, population‐based tumor testing program in HGSC is effective in identifying BRCA1/2 PV both for the purposes of determining treatment eligibility, and as a potential screen for hereditary cancer syndromes. The gene discussed is BRCA1; the disease is neoplasm.